Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is proud to announce the launch of its D
The Nobel Prize in Physiology or Medicine awarded
This year, the Hamburg based life sciences company
Alembic Pharmaceuticals Ltd., t
Since it’s an ingredient in so many foods, you h
Dear Readers, Welcome to the latest issue of Micr
Mumbai, India; February 08, 2020: Cipla Ltd. (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced the acquisition of nutrition products’ portfolio from Wanbury Ltd. Cipla has acquired 4 brands — CPink, CDense, Productiv and Folinine to further strengthen its presence in women’s health.
The nutraceutical products, to be sold under the 4 umbrella brands, would address various health needs for conditions arising due to nutritional deficiencies or insufficiencies. This includes supplements such as multivitamins, multi-mineral and antioxidants for adolescent girls, pregnant and lactating women, women going through menopause and for male and female reproductive health.
Nikhil Chopra, Head India Business, Cipla Limited, said: “We are focused on strengthening our play in the women’s health segment by amplifying our four-decade long presence in this category. Through this newly acquired portfolio, we shall be catering to a wide range of patient needs including nutritional deficiencies, bone health and sexual health”.
As per (IQVIA MAT Dec’19), the above molecules previously commercialized by Wanbury Ltd have a market size of INR 3,100 Cr in India with sales value of INR 59.6 Cr.
